https://www.businesswire.com/news/home/20180607005921/en/

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2018--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering from severe Staphylococcus aureus ( S. aureus ) infections, who received treatment with AB-SA01, AmpliPhi’s investigational bacteriophage drug candidate. The presentation will be made at the American Society for Microbiology (ASM) Microbe 2018 annual meeting, being held June 7-11, 2018 in Atlanta. The abstract can be viewed here.

Poster Presentation:

Title: AAR LB16 - Bacteriophages as adjuvant therapy for the treatment of severe staphylococcal sepsis Date and time: Friday, June 8, 2018, 11 a.m. - 1 p.m. EDT Session: 048 - FRIDAY - AAR Late-breakers Track: AAR Location: Exhibit and Poster Hall, Building B, Halls B2-B5, Georgia World Congress Center, Atlanta, Georgia Presenter: Dr. Jonathan Iredell, Westmead Hospital and Westmead Institute for Medical Research